This is a Cleveland news story, published by BGR, that relates primarily to Ozempic and Wegovy news.
For more Cleveland news, you can click here:
more Cleveland newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from BGR, you can click here:
more news from BGROtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
antidiabetic drugs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest smoking cessation medication prescriptions news, semaglutide news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
other antidiabetes medicationsBGR
•
71% Informative
Semaglutide, like Ozempic and Wegovy , are intended to help people with diabetes lower their blood glucose levels.
The active ingredient has another notable side effect: reducing the desire to smoke.
Researchers from Cleveland and Maryland published their findings in Annals of Internal Medicine .
VR Score
56
Informative language
47
Neutral language
56
Article tone
informal
Language
English
Language complexity
67
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
4
Source diversity
3
Affiliate links
no affiliate links